CLIMB BIO INC (CLYM) Fundamental Analysis & Valuation

NASDAQ:CLYM • US28658R1068

Current stock price

6.56 USD
-0.39 (-5.61%)
At close:
7 USD
+0.44 (+6.71%)
After Hours:

This CLYM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CLYM Profitability Analysis

1.1 Basic Checks

  • CLYM had negative earnings in the past year.
  • In the past year CLYM has reported a negative cash flow from operations.
  • In the past 5 years CLYM always reported negative net income.
  • CLYM had a negative operating cash flow in each of the past 5 years.
CLYM Yearly Net Income VS EBIT VS OCF VS FCFCLYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • CLYM's Return On Assets of -35.68% is in line compared to the rest of the industry. CLYM outperforms 59.38% of its industry peers.
  • With a decent Return On Equity value of -37.30%, CLYM is doing good in the industry, outperforming 69.44% of the companies in the same industry.
Industry RankSector Rank
ROA -35.68%
ROE -37.3%
ROIC N/A
ROA(3y)-33.83%
ROA(5y)-33.01%
ROE(3y)-34.94%
ROE(5y)-34.22%
ROIC(3y)N/A
ROIC(5y)N/A
CLYM Yearly ROA, ROE, ROICCLYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • CLYM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLYM Yearly Profit, Operating, Gross MarginsCLYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. CLYM Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CLYM has been reduced compared to 1 year ago.
  • CLYM has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CLYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLYM Yearly Shares OutstandingCLYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CLYM Yearly Total Debt VS Total AssetsCLYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 22.82 indicates that CLYM is not in any danger for bankruptcy at the moment.
  • CLYM has a better Altman-Z score (22.82) than 89.94% of its industry peers.
  • There is no outstanding debt for CLYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.82
ROIC/WACCN/A
WACCN/A
CLYM Yearly LT Debt VS Equity VS FCFCLYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • CLYM has a Current Ratio of 15.16. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
  • CLYM's Current ratio of 15.16 is amongst the best of the industry. CLYM outperforms 92.46% of its industry peers.
  • CLYM has a Quick Ratio of 15.16. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 15.16, CLYM belongs to the top of the industry, outperforming 92.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.16
Quick Ratio 15.16
CLYM Yearly Current Assets VS Current LiabilitesCLYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. CLYM Growth Analysis

3.1 Past

  • CLYM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.52%, which is quite impressive.
EPS 1Y (TTM)58.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CLYM is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.33% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.85%
EPS Next 2Y-13.3%
EPS Next 3Y-14.21%
EPS Next 5Y-22.33%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLYM Yearly Revenue VS EstimatesCLYM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 200M 400M 600M 800M
CLYM Yearly EPS VS EstimatesCLYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. CLYM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CLYM. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLYM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLYM Price Earnings VS Forward Price EarningsCLYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLYM Per share dataCLYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • A cheap valuation may be justified as CLYM's earnings are expected to decrease with -14.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.3%
EPS Next 3Y-14.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CLYM Dividend Analysis

5.1 Amount

  • No dividends for CLYM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLYM Fundamentals: All Metrics, Ratios and Statistics

CLIMB BIO INC

NASDAQ:CLYM (4/2/2026, 8:15:51 PM)

After market: 7 +0.44 (+6.71%)

6.56

-0.39 (-5.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)N/A
Inst Owners53.67%
Inst Owner ChangeN/A
Ins Owners0.3%
Ins Owner Change-67.67%
Market Cap313.37M
Revenue(TTM)N/A
Net Income(TTM)-59.85M
Analysts88.89
Price Target15.67 (138.87%)
Short Float %3.81%
Short Ratio3.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.2%
Min EPS beat(2)-29.39%
Max EPS beat(2)-27%
EPS beat(4)1
Avg EPS beat(4)-31.98%
Min EPS beat(4)-102.61%
Max EPS beat(4)31.11%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)34.43%
PT rev (3m)60.04%
EPS NQ rev (1m)-26.84%
EPS NQ rev (3m)-31.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.95
P/tB 1.95
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS3.36
TBVpS3.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.68%
ROE -37.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.83%
ROA(5y)-33.01%
ROE(3y)-34.94%
ROE(5y)-34.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 191.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.16
Quick Ratio 15.16
Altman-Z 22.82
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-0.85%
EPS Next 2Y-13.3%
EPS Next 3Y-14.21%
EPS Next 5Y-22.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-151.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.28%
EBIT Next 3YN/A
EBIT Next 5Y-12.72%
FCF growth 1Y-169.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-249.29%
OCF growth 3YN/A
OCF growth 5YN/A

CLIMB BIO INC / CLYM Fundamental Analysis FAQ

What is the fundamental rating for CLYM stock?

ChartMill assigns a fundamental rating of 3 / 10 to CLYM.


What is the valuation status of CLIMB BIO INC (CLYM) stock?

ChartMill assigns a valuation rating of 0 / 10 to CLIMB BIO INC (CLYM). This can be considered as Overvalued.


Can you provide the profitability details for CLIMB BIO INC?

CLIMB BIO INC (CLYM) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CLIMB BIO INC?

The Earnings per Share (EPS) of CLIMB BIO INC (CLYM) is expected to decline by -0.85% in the next year.